Layla+Celecoxib coming soon

The drug price is higher than the single drug

High-performance expectations

Pay attention to whether the improved new drug is calculated

a new osteoarthritis complex developed by PMG Korea.

A compound that combines different osteoarthritis treatments based on natural products and synthesis is expected to be released on the 1st of next month.

 

20 companies are selling their products, and it is noteworthy whether it will create a new wind in the osteoarthritis treatment market.

 

The original drug ingredient of Danggui, Mogwa, Bangpung, Sokdan, Ogapi, Wooseul, Wiryeongseon, Yukye, Jingyo, Cheongung, Cheonma, and Honghwa 25% Ethanol Yeonjo X is Layla of Korea PMG Pharmaceutical.

 

PMG Pharmaceuticals Korea succeeded in developing a compound that combines the ingredient of Layla tablet with the ingredient of COX-2 inhibitor 'Serecoxib', and was approved for the item 'Reladisuine' in August.

 

The drug demonstrated superiority to the control group in a phase 3 clinical trial of 356 patients with knee osteoarthritis (177 in the trial group and 179 in the control group) in a 100 mm pain VAS change in activity at week 8 compared to the baseline, the primary efficacy evaluation variable.

 

In the same month, 19 items with the same ingredients were also licensed.

 

These items are consignment items that have been approved through joint development with Korea PMG Pharmaceuticals.

 

All product production is handled by PMG Korea Pharmaceutical.

 

The items are Kyungdong Pharmaceutical's 'Selec Duojeong', Guangdong Pharmaceutical's Cox Duojeong', Daewoong Bio's Beacoxis Plus Jeong', Dongkuk Pharmaceutical's Selebron Jeong', Vascan Bio-Pharmaceutical 'Sebkan Plus Jeong', Samil Pharmaceutical 'Lecoxjeong', Samjin Pharmaceutical 'Asbon Plus Jeong', CMG Pharmaceutical 'Coks Plus Jeong', Anguk Pharmaceutical 'Cox2 Plus Jeong', Alico Pharmaceutical 'Raycelco Jeong', HLB Pharmaceutical 'Rex Duojeong', Unimed Pharmaceutical 'Bon Ekox', Ilhwa 'Sele Inajeong', Jenewon Science 'Sereduojeong', Jinyang Pharmaceutical 'Aduria Diess', Palm Genesis 'Sejoinjeong', Pungjeong', Korea Techon Pharmaceutical 'Unira-on Pharmaceutical 'Unira Plus These are expected to be priced by the compound calculation criteria.

 

The compound is calculated at 53.55% sum of the single component before patent expiration.

 

Both ingredients have expired patents, so it is likely that they will be set at the sum of the highest price of a single component.

 

Then, the drug price is expected to be calculated at 567 won, which is the maximum price of ethanol Yeonjo X, which is 220 won for 25% ethanol Yeonjo X and 347 won for Celecoxib 100 mg 347 won.

 

However, if the Ministry of Food and Drug Safety recognizes it as an improved new drug, the drug price will be added at 58.5% instead of 53.55%, so there is also interest in whether to designate an improved new drug.

 

Some analysts say that in the case of eperison + aceclofenac complex in December last year, only Aju Pharm, a trustee, received an added-improved new drug, so there may be a difference in the drug price depending on whether it is above or not.

 

Regardless, with a combination of the two ingredients, each pharmaceutical company has performance expectations in that it can receive a higher drug price than a single drug.

 

In particular, PMG Pharmaceutical, which sells the original Layla, has seen a decline in earnings due to drug price adjustments since the appearance of Layla generic, so expectations for this product are different.

 

Moreover, since it is also in charge of consignment production to 19 companies, it is expected to add CMO performance to its own product sales performance.

 

The domestic osteoarthritis treatment market is estimated to be about 500 billion won.

 

The launch of this complex is expected to be an opportunity to create a new competitive landscape.